Veeva财报前预期检验：股价已因AI CRM动能上涨38%，但当前新闻未披露业绩结果

Fed’s preferred inflation index matches prior month on annualized basis in July
Veeva Systems Inc. reports fiscal second-quarter results Wednesday after the market close, with investors scrutinizing whether the life sciences software provider can justify a 38% stock rally since its last earnings report in early June.
Analysts expect the company to post earnings of $2.22 per share on revenue of $905.41 million for the quarter ended July 31, representing year-over-year growth of 11.6% and 14.7%, respectively. The revenue forecast implies sequential growth of 2.5% from the prior quarter’s $882.9 million, though the EPS estimate dips slightly from last quarter’s $2.24 actual result.
The stock carries a consensus Buy rating from 29 analysts, with 20 Buy ratings, eight Holds and one Sell. The mean price target of $255.93 implies 3.7% upside from the current $246.78 price. EPS estimates have remained stable over the past two months, as have revenue estimates, suggesting analysts have already baked strong expectations into their models.
Veeva announced major customer wins just hours before the report, saying Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally and that Vault CRM, which includes the Agentic Call Report to generate Commercial Evidence, was also selected by Biogen. The timing underscores momentum in Veeva’s CRM business as it competes against Salesforce.
What Investors Are Watching
Analysts will focus on three key areas when management provides guidance. First, progress on Veeva’s artificial intelligence strategy and Vault CRM adoption among top pharmaceutical companies. Following Eli Lilly’s recent CRM commitment, investors want clarity on how many of the top 20 pharma firms Veeva has converted—management has targeted 13 to 14 conversions—and details on AI monetization plans.
Second, growth in research and development subscription revenue. Street estimates model 17% year-over-year growth, but the metric averaged 20% over the prior three quarters, suggesting potential upside if Veeva’s pharma and biotech customers continue ramping spending.
Third, whether Veeva beats consensus and raises full-year guidance. With the stock up sharply, several analysts noted expectations are elevated. The question is whether management flows any second-quarter outperformance into increased full-year targets, particularly for operating margins, which grew 28% in the latest reported period.
Veeva exceeded expectations in its fiscal first quarter, delivering EPS of $2.24 versus the $2.14 consensus and revenue of $882.9 million against $857.75 million estimates. The company surprised by 4.67% on earnings and 2.93% on revenue.
For a stock trading at 26.7 times forward earnings—well above its historical average—Wednesday’s results will test whether Veeva’s AI capabilities and deepening pharmaceutical relationships can sustain premium valuation multiples in an environment where software investors are increasingly selective.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.